United Kingdom · Question · Written question
UIN 38239
Relugolix/estradiol/norethisterone: Northern Ireland
Original
Introduced
13 March 2025
Last action
19 March 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
19 March 2025
Summary
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence's recommendation of relugolix-estradiol-norethisterone for routine NHS use to treat endometriosis will extend to Northern Ireland.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
13 March 2025
Written question
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health and Care Excellence's recommendation of relugolix-estradiol-norethisterone for routine NHS use to treat endometriosis will extend to Northern Ireland.
Source: Commons
19 March 2025
Answer
The National Institute for Health and Care Excellence (NICE) makes recommendations on whether new medicines should be routinely funded by the National Health Service in England. NICE published final draft guidance on 13 March 2025 that recommends relugoli...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-03-13/38239
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1784571
- uk · wq-1784571 · source updated 19 March 2025